Impact News +++ Berger Montague: Six Flags Entertainment Corp. (FUN) Deadline Approaching: Berger Montague Advises Investors of... (Newsfile) +++ SIX FLAGS Aktie +5,56%

GENMAB Aktie

>GENMAB Aktienkurs

278.7 EUR -2.7% (Tradegate)

Ask: 280.6 EUR / 20 Stück

Bid: 278.7 EUR / 20 Stück

Tagesumsatz: 330 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

GENMAB Aktie über LYNX handeln

Intraday

1 Jahr

>GENMAB Performance

1 Woche: +2,9%

1 Monat: +4,1%

3 Monate: +15,6%

6 Monate: +61,8%

1 Jahr: +44,7%

laufendes Jahr: +42,1%

>GENMAB Aktie

Name:

GENMAB AS DK 1

Land:

Dänemark

Sektor:

Gesundheit

ISIN/ Wkn:

DK0010272202 / 565131

Symbol/ Ticker:

GE9 (Frankfurt)

Kürzel:

FRA:GE9, ETR:GE9, GE9:GR

Index:

Webseite:

https://www.genmab.com/

Profil:

Genmab A/S is an international biotechnology compa..
>Volltext..

Marktkapitalisierung:

17470.6 Mio. EUR

Unternehmenswert:

14694.46 Mio. EUR

Umsatz:

3212.81 Mio. EUR

EBITDA:

1235.02 Mio. EUR

Nettogewinn:

1331.76 Mio. EUR

Gewinn je Aktie:

21.28 EUR

Schulden:

120.16 Mio. EUR

Liquide Mittel:

1490.09 Mio. EUR

Operativer Cashflow:

1148.55 Mio. EUR

Bargeldquote:

4.6

Umsatzwachstum:

21.68%

Gewinnwachstum:

114.88%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

GENMAB

Letzte Datenerhebung:

29.12.25

>GENMAB Kennzahlen

Aktien/ Unternehmen:

Aktien: 61.6 Mio. St.

Frei handelbar: 94.81%

Leerverk. Aktien: -

Rückkaufquote: 2.1%

Mitarbeiter: 2682

Umsatz/Mitarb.: 0.94 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 5.44%

Bewertung:

KGV: 13.43

KGV lG: 18.37

KUV: 5.37

KBV: 3.59

PEG-Ratio: 0.11

EV/EBITDA: 11.9

Rentabilität:

Bruttomarge: 94.28%

Gewinnmarge: 41.45%

Operative Marge: 36.58%

Managementeffizenz:

Gesamtkaprendite: 23.73%

Eigenkaprendite: 29.21%

>GENMAB Peer Group

Es sind 20 Aktien bekannt.

>GENMAB Chart & Kurs - Tradegate

>GENMAB News

29.12.25 - 16:15	Genmab ends development of late-stage oncology asset acasunlimab (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.12.25 - 15:24	Genmab To Discontinue Clinical Development Of Acasunlimab To Focus On Priority Programs (AFX)
	BRUSSELS (dpa-AFX) - Genmab A/S (GMAB), Monday announced the decision to discontinue further clinical development of acasunlimab to focus on programs with the highest potential impact, such as EPK......

29.12.25 - 14:15	Genmab Portfolio Prioritization Update (GlobeNewswire EN)
	Company Announcement...

12.12.25 - 07:42

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period (Business Wire)

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by end of 2029 COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab's shift to a wholly owned model, expanding and diversifying the company's revenue, driving sustained growth into the next decade and contributing to Genmab's evolution into a biotechnology leader. “The Merus acquisition marks a pivotal step in the delivery of Genmab's long-term strategy and strength...

11.12.25 - 08:03	Genmab to Hold 2025 R&D Update and ASH Data Review Meeting (GlobeNewswire EN)
	Media Release...

09.12.25 - 11:45	Genmab: Nach wie vor ein schwacher Ausblick (LYNX)
	Genmab überrascht Quartal für Quartal. Viermal infolge mindestens 29 % mehr Gewinn als erwartet. Schlafen die Prognostiker?...

08.12.25 - 22:33	Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) (GlobeNewswire EN)
	Media ReleaseCOPENHAGEN, Denmark; December 8, 2025...

08.12.25 - 04:36	Genmab: Phase 3 Trial Shows EPKINLY + R2 Cuts Progression Risk By 79% And Achieves 95% ORR In FL (AFX)
	WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) announced primary results from the pivotal Phase 3 EPCORE FL-1 study, evaluating fixed-duration EPKINLY (epcoritamab-bysp) in combination with rituximab an......

07.12.25 - 13:54	Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma (GlobeNewswire EN)
	Media ReleaseCOPENHAGEN, Denmark; December 7, 2025...

06.12.25 - 18:30	Genmab Reports Promising Clinical Trial Results For Fixed-Duration Epcoritamab In Lymphoma (AFX)
	TOKYO (dpa-AFX) - Genmab A/S (GMAB) announced updated findings from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered, T-cell engaging antibody.The data h......

06.12.25 - 15:33	Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) (GlobeNewswire EN)
	Media ReleaseCOPENHAGEN, Denmark; December 6, 2025...

03.12.25 - 21:06	Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes (GlobeNewswire EN)
	Media Release...

01.12.25 - 22:27	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire EN)
	Company Announcement...

28.11.25 - 01:12	Genmab (GMAB) Q3 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

20.11.25 - 21:06	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire EN)
	Company Announcement...

19.11.25 - 18:57	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire EN)
	Company Announcement...

19.11.25 - 04:49	Genmab Secures FDA Approval Of EPKINLY Combination Therapy For R/R Follicular Lymphoma (AFX)
	WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) announced that the U.S. Food and Drug Administration approved EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) for ......

19.11.25 - 04:12	Genmab Announces Pricing Of Private Offering Of Senior Secured Notes And Senior Unsecured Notes (AFX)
	WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) announced that the company and its wholly owned subsidiary Genmab Finance LLC have priced their offering of $1.5 billion of 6.250% senior secured notes due......

18.11.25 - 22:54	Genmab Wraps Up Leveraged Finance′s Biggest M&A Deal Since April (Bloomberg)
	Genmab A/S completed the US leveraged finance market's largest acquisition funding since April, raising $4.5 billion through junk bonds and a leveraged loan....

18.11.25 - 22:03	Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility (GlobeNewswire EN)
	Media Release...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ich bete, um zu glauben. Glaube ich. - Peter Esterházy

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram